Literature DB >> 8400324

Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.

S Yamasaki1, N Kan, T Harada, Y Ichinose, Y Moriguchi, L Li, T Sugie, H Kodama, K Satoh, K Ohgaki.   

Abstract

We treated 33 patients with liver metastases from breast cancer by immuno-chemotherapy including adoptive cell transfer between 1987 and 1992. In this study, we examined the change of immunological parameters in the peripheral blood lymphocytes and interleukin-2 (IL-2)-cultured lymphocytes, in primary vs. metastatic breast cancer patients and before vs. after treatment. Moreover, we examined their correlation with therapeutic response and survival after treatment. The immunological parameters used were in vitro natural killer cell activity (% lysis of K562), in vitro autologous tumor-killing activity (% lysis against autologous freshly isolated tumor cells), and proliferation of lymphocytes stimulated with IL-2 and autologous sonicated tumor extract antigen in mixed culture (IL-2-enhanced MLTR). When compared with primary breast cancer patients, patients with liver metastases showed a significant decrease in % lysis of K562 and autologous tumor cells. After treatment, the stimulation index in IL-2-enhanced MLTR increased significantly from the pretreatment level and correlated with survival after treatment. Moreover, non-specific immunological parameters (performance status, lymphocyte count, and transferred cell count and proliferation rate of cultured lymphocytes) were significantly associated with response and prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400324     DOI: 10.1007/bf00682700

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients.

Authors:  A Uchida; Y Kariya; N Okamoto; K Sugie; T Fujimoto; M Yagita
Journal:  J Natl Cancer Inst       Date:  1990-11-07       Impact factor: 13.506

2.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

Review 3.  Development of immunotherapeutic strategies for the treatment of malignant neoplasms.

Authors:  J E Talmadge
Journal:  Biotherapy       Date:  1992

Review 4.  The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.

Authors:  J E Talmadge; R B Herberman
Journal:  Cancer Treat Rep       Date:  1986-01

5.  Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.

Authors:  T Hori; K Mise; N Kan; T Okino; K Satoh; S Yamasaki; Y Teramura; T Harada; K Ohgaki; H Kodama
Journal:  Biotherapy       Date:  1992

6.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

Authors:  G M Clark; G W Sledge; C K Osborne; W L McGuire
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

7.  Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.

Authors:  P O Livingston; S Cunningham-Rundles; G Marfleet; C Gnecco; G Y Wong; G Schiffman; W E Enker; M K Hoffman
Journal:  J Biol Response Mod       Date:  1987-08

8.  Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.

Authors:  N Kan; K Ohgaki; T Inamoto; H Kodama
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.

Authors:  N Kan; T Okino; M Nakanishi; K Sato; K Mise; S Yamasaki; Y Teramura; K Ohgaki; T Tobe
Journal:  Biotherapy       Date:  1989

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators.

Authors:  Bonnie A McGregor; Michael H Antoni
Journal:  Brain Behav Immun       Date:  2008-08-22       Impact factor: 7.217

2.  Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis.

Authors:  Lisa M Thornton; Barbara L Andersen; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2008-03-08       Impact factor: 6.968

3.  Mindfulness and its efficacy for psychological and biological responses in women with breast cancer.

Authors:  Elisabeth Kenne Sarenmalm; Lena B Mårtensson; Bengt A Andersson; Per Karlsson; Ingrid Bergh
Journal:  Cancer Med       Date:  2017-04-18       Impact factor: 4.452

4.  Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in women recovering from breast cancer treatment [ISRCTN08045231].

Authors:  John M Saxton; Amanda Daley; Nicola Woodroofe; Robert Coleman; Hilary Powers; Nanette Mutrie; Vanessa Siddall; Helen Crank
Journal:  BMC Cancer       Date:  2006-02-09       Impact factor: 4.430

5.  Mindfulness based stress reduction study design of a longitudinal randomized controlled complementary intervention in women with breast cancer.

Authors:  Elisabeth Kenne Sarenmalm; Lena B Mårtensson; Stig B Holmberg; Bengt A Andersson; Anders Odén; Ingrid Bergh
Journal:  BMC Complement Altern Med       Date:  2013-10-02       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.